Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Science Translational Medicine|November 29, 2019
Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitisNeeta B Amin, Santos Carvajal-Gonzalez, Julie Purkal, et al.Journal of Lipid Research|August 25, 2024
Murine HSD17β13 does not control liver steatosis and modestly impacts fibrosis in a sex- and diet-specific mannerJustin D Crane, Ornella Barrandon, Bryan Faherty, et al.Cellular and Molecular Gastroenterology and Hepatology|June 12, 2020
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model SystemsTrenton T Ross, Collin Crowley, Kenneth L Kelly, et al.Nature Medicine|October 12, 2021
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trialsRoberto A Calle, Neeta B Amin, Santos Carvajal-Gonzalez, et al.Molecular Metabolism|March 5, 2021
Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunctionJemy A Gutierrez, Wei Liu, Sylvie Perez, et al.Journal of Medicinal Chemistry|November 2, 2022
Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic SteatohepatitisKentaro Futatsugi, Shawn Cabral, Daniel W Kung, et al.Journal of Medicinal Chemistry|August 19, 2020
Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver TargetingKim Huard, Aaron C Smith, Gregg Cappon, et al.Pageof 1